difelikefalin


( Last Updated : August 3, 2022)
Generic Name:
difelikefalin
Project Status:
Pending
Therapeutic Area:
Chronic kidney disease
Manufacturer:
Otsuka Canada Pharmaceutical Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0752-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of moderate to severe pruritus associated with chronic kidney disease in adult patients on hemodialysis.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of moderate to severe pruritus associated with chronic kidney disease in adult patients on hemodialysis.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.